Apogee Enterprises, Inc. Nasdaq: APOG January 2026 Fiscal 2026 Third Quarter Earnings Call University of Washington, NanoES – Seattle © Aaron Leitz Photography; courtesy of ZGF Non-GAAP Measures & Forward-Looking Statements This presentation contains measures of financial performance that are not defined by U.S. GAAP. We believe that these measures provide useful information and include these measures in other communications to investors. For each of these non-GAAP financial measures, we provide a reconcili ...

Cal-Maine Foods Reports Second Quarter Fiscal 2026 Results NASDAQ: CALM | January 7, 2026 Cautionary Statements This presentation contains numerous forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act") relating to our business, including, potential future supply of and demand for our products, potential future corn and soybean price trends, potential future impact on our bu ...

Financial Performance - Sales increased by 16% from Q2 FY25 to Q2 FY26[9] - Adjusted EBITDA increased by 23% from Q2 FY25 to Q2 FY26[9] - Adjusted EPS increased by 31% from Q2 FY25 to Q2 FY26[9] - Parts Supply sales increased by 29% from Q2 FY25 to Q2 FY26[28] - Integrated Solutions sales increased by 8% from Q2 FY25 to Q2 FY26[38] - Adjusted operating margin increased from 92% to 102%[24] Acquisitions and Strategic Initiatives - Acquired ADI, a distributor of electronic components and assemblies, with $149 million in sales and $15 million in EBITDA[9, 13] - Acquired HAECO Americas, the 2nd largest independent North American heavy maintenance provider, securing $850 million+ in new multi-year contracts[9, 15] - Announced an agreement to acquire Aircraft Reconfig Technologies for $35 million[9, 20] Balance Sheet and Leverage - Net leverage decreased by 109x since the Product Support acquisition[41] - The company is targeting a net leverage ratio of 20x – 25x[42, 46] Guidance - Q3 FY26 total sales growth is projected to be 20%-22%, with organic sales growth of 8%-11%[53]

Financial Performance - Penguin Solutions' net sales for Q1 FY26 were $343 million, a 1% increase year-over-year (YoY)[10] - The non-GAAP gross margin was 30.0%, a decrease of 0.8 percentage points YoY[10] - Non-GAAP operating income reached $42 million, up 1% YoY, with a non-GAAP operating margin of 12.1%, up 0.1 percentage points YoY[10] - Non-GAAP diluted earnings per share (EPS) remained flat YoY at $0.49[10] Segment Performance - Advanced Computing net sales were $151 million in Q1, up 9% compared to Q4 FY25[25] - Integrated Memory revenue was $137 million in Q1, a significant increase of 41% YoY[27] - Optimized LED net sales were $55 million in Q1, down 18% YoY, but achieved an operating income of $3.5 million, up 24% sequentially[30] Balance Sheet and Cash Flow - Net accounts receivable stood at $342 million[43] - Inventory was valued at $213 million[43] - Cash, cash equivalents, and short-term investments totaled $461 million at the end of the period[43] - Net cash from operating activities from continuing operations was $31 million[43] Stock Repurchase - Penguin Solutions repurchased 791,000 shares for $15 million in Q1 FY26[46] - Since April 2022, the company has repurchased 7.4 million shares for a total of $128 million[46] FY26 Outlook - Penguin Solutions anticipates net sales growth of 6% YoY, with a potential variance of +/- 10%[48] - The projected gross margin is 29% +/- 1%[48] - Operating expenses are expected to be $250 million +/- $10 million on a non-GAAP basis[48] - Non-GAAP diluted earnings per share are forecasted at $2.00 +/- $0.25[48]

ARO-INHBE Clinical Data - ARO-INHBE achieved a mean maximum reduction of 85% in serum Activin E after a single 400 mg dose, with a maximum observed reduction of 94%[80, 147] - ARO-INHBE monotherapy reduced visceral fat by 9.9% after a single dose at week 16 and 15.6% after two doses at week 24[82, 85, 147] - In obese diabetic patients, ARO-INHBE combined with tirzepatide doubled weight loss compared to tirzepatide alone, showing a 9.4% weight loss at week 16 versus 4.8% with tirzepatide alone[103, 105, 147] - Combination therapy with ARO-INHBE and tirzepatide in obese diabetic patients resulted in a 23.2% reduction in visceral fat, a 15.4% reduction in total fat, and a 76.7% reduction in liver fat, approximately a 3-fold improvement compared to tirzepatide alone across these measures[106, 107, 148] ARO-ALK7 Clinical Data - ARO-ALK7 demonstrated a mean reduction of 88% in ALK7 mRNA, confirming the TRiM platform's ability to silence adipocyte gene expression, with a maximum reduction of 94%[135, 148] - ARO-ALK7 showed a rapid dose-dependent reduction in visceral fat of up to 14% (placebo-adjusted) after a single dose[137, 148] General Summary - Both ARO-INHBE and ARO-ALK7 demonstrated favorable safety profiles in their respective monotherapy and combination therapy trials[113, 139] - The company plans to initiate Phase 2b studies as soon as possible and expand the obesity pipeline with new targets, including dimers[151] - Arrowhead's growth drivers in 2026 and beyond include potential multi-billion-dollar opportunity from Phase 3 studies of plozasiran in severe hypertriglyceridemia, first clinical readout of ARO-DIMER-PA targeting PCSK9 and APOC3 in 2H 2026, and emerging CNS pipeline with systemic delivery via SC administration[155]

Strategic Update The information in this document contains forward-looking statements about future events and circumstances and their effects upon revenues, expenses and business opportunities. Generally speaking, any statement in this document not based upon historical fact is a forward-looking statement. Forward-looking statements can also be identified by the use of forward-looking or conditional words, such as "could," "should," "can," "continue," "estimate," "forecast," "intend," "look," "may," "will," ...

TPG and Jackson Establish Long-Term Strategic Partnership January 2026 Important Notices This presentation is being provided by TPG Inc. ("TPG," "we," "our," "us," or the "Company") solely for informational purposes for its public stockholders. To the maximum extent permitted by law, none of us or our affiliates, directors, officers, partners, employees, agents, or advisors or any other person accepts any liability related to the use or misuse of the information contained in this presentation. The Company a ...

Second Quarter FY 2026 Earnings Results January 6, 2026 Forward looking statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives o ...

ATI-052: Anti-TSLP x IL-4Rα Bispecific Antibody Program Highly Potent and Bioactive Investigational Product Candidate January 6, 2026 Disclaimer and Cautionary Note Regarding Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "anticipate," "believe," "expect," "intend," "may," ...

Title text 2 Zumilokibart (APG777) Asthma Phase 1b Interim Results January 6, 2026 Disclaimers and Forward-looking Statements This presentation contains certain "forward-looking statements" within the meaning of applicable securities laws. Other than statements of historical facts, all statements included in this presentation are forward-looking statements, including statements about the potential for zumilokibart (APG777) in asthma; Apogee's plans for its current and future product candidates and programs; ...